PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: PIPELINE PART 08: MARKET SEGMENTATION BY PRODUCT • Segmentation by product • Comparison by product • Small molecules – Market size and forecast 2017-2022 • Biologics – Market size and forecast 2017-2022 • Market opportunity by product PART 09: CUSTOMER LANDSCAPE PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Technological advances • Increasing patient support programs • Strategic alliances PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • F. Hoffmann-La Roche • Merck Sharp & Dohme • Novartis • Pfizer • Spectrum Pharmaceuticals PART 16: APPENDIX • List of abbreviations     Exhibit 01: Parent market Exhibit 02: Global NHL therapeutics market segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global DLBCL therapeutics market – Market size and forecast 2017-2022 ($ mn) Exhibit 09: Global DLBCL therapeutics market – Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Pipeline landscape by development phase 2017-2018 Exhibit 19: Late-stage pipeline molecules for treatment of DLBCL 2017-2018 Exhibit 20: Global DLBCL therapeutics market by product – Market share 2017-2022 (%) Exhibit 21: Comparison by product Exhibit 22: Global DLBCL therapeutics market by small molecules – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Global DLBCL therapeutics market by small molecules – Year-over-year growth 2018-2022 (%) Exhibit 24: Global DLBCL therapeutics market by biologics – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Global DLBCL therapeutics market by biologics – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by product Exhibit 27: Customer landscape Exhibit 28: Global DLBCL therapeutics market – Market share by geography 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: DLBCL therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 31: DLBCL therapeutics market in Americas – Year-over-year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: DLBCL therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 34: DLBCL therapeutics market in EMEA – Year-over-year growth 2018-2022 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: DLBCL therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 37: DLBCL therapeutics market in APAC – Year-over-year growth 2018-2022 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Market opportunity Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: F. Hoffmann-La Roche – Overview Exhibit 46: F. Hoffmann-La Roche – Business segments Exhibit 47: F. Hoffmann-La Roche – Organizational developments Exhibit 48: F. Hoffmann-La Roche – Geographic focus Exhibit 49: F. Hoffmann-La Roche – Segment focus Exhibit 50: F. Hoffmann-La Roche – Key offerings Exhibit 51: F. Hoffmann-La Roche – Key customers Exhibit 52: Merck Sharp & Dohme – Overview Exhibit 53: Merck Sharp & Dohme – Business segments Exhibit 54: Merck Sharp & Dohme – Organizational developments Exhibit 55: Merck Sharp & Dohme – Geographic focus Exhibit 56: Merck Sharp & Dohme – Segment focus Exhibit 57: Merck Sharp & Dohme – Key offerings Exhibit 58: Merck Sharp & Dohme – Key customers Exhibit 59: Novartis – Overview Exhibit 60: Novartis – Business segments Exhibit 61: Novartis – Organizational developments Exhibit 62: Novartis – Geographic focus Exhibit 63: Novartis – Segment focus Exhibit 64: Novartis – Key offerings Exhibit 65: Novartis – Key customers Exhibit 66: Pfizer – Overview Exhibit 67: Pfizer – Business segments Exhibit 68: Pfizer – Organizational developments Exhibit 69: Pfizer – Geographic focus Exhibit 70: Pfizer – Segment focus Exhibit 71: Pfizer – Key offerings Exhibit 72: Pfizer – Key customers Exhibit 73: Spectrum Pharmaceuticals: Overview Exhibit 74: Spectrum Pharmaceuticals – Business segments Exhibit 75: Spectrum Pharmaceuticals – Organizational developments Exhibit 76: Spectrum Pharmaceuticals – Geographic focus Exhibit 77: Spectrum Pharmaceuticals – Key offerings Exhibit 78: Spectrum Pharmaceuticals – Key customers

F. Hoffmann-La Roche Merck Sharp & Dohme Novartis Pfizer Spectrum Pharmaceuticals